|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104781 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-23 17:12:42 |
|
注册时间: Date of Registration: |
2025-06-23 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
慢性肾脏病3-5期非透析患者生命质量发展轨迹及影响因素研究 |
|
Public title: |
Research on the Developmental Trajectory of Quality of Life and Its Influencing Factors in Non-Dialysis Patients with Stage 3-5 Chronic Kidney Disease |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
慢性肾脏病3-5期非透析患者生命质量发展轨迹及影响因素研究 |
|
Scientific title: |
Research on the Developmental Trajectory of Quality of Life and Its Influencing Factors in Non-Dialysis Patients with Stage 3-5 Chronic Kidney Disease |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
周玲 |
研究负责人: |
周玲 |
|
Applicant: |
Zhou Ling |
Study leader: |
Zhou Ling |
|
申请注册联系人电话: Applicant telephone: |
+86 159 5191 0334 |
研究负责人电话:
Study leader's |
+86 159 5191 0334 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1246943709@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
1246943709@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市秦淮区汉中路155号 |
研究负责人通讯地址: |
江苏省南京市秦淮区汉中路155号 |
|
Applicant address: |
155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China |
Study leader's address: |
155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江苏省中医院 |
||
|
Applicant's institution: |
Jiangsu Provincial Hospital of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
江苏省中医院 |
||
|
Affiliation of the Leader: |
Jiangsu Provincial Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2025NL-071-02 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
南京中医药大学附属医院(江苏省中医院)伦理委员会 |
||
|
Name of the ethic committee: |
Research Ethics Committee of Jiangsu Provincial Hospital of Traditional Chinese Medicine (The Affiliated Hospital of Nanjing University of Chinese Medicine) |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-03-18 00:00:00 | ||
|
伦理委员会联系人: |
王卯 |
||
|
Contact Name of the ethic committee: |
Wang Mao |
||
|
伦理委员会联系地址: |
江苏省南京市秦淮区汉中路155号 |
||
|
Contact Address of the ethic committee: |
155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 25 8656 0515 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
江苏省中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jiangsu Provincial Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市秦淮区汉中路155号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
155 Hanzhong Road, Qinhuai District, Nanjing, Jiangsu Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
慢性肾脏病 |
||||||||||||||||||||||
|
Target disease: |
Chronic Kidney Disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
1.探究 CKD3-5 期非透析患者生命质量不同发展轨迹。 2.基于 Wilson-Cleary 健康相关生命质量理论探究 CKD3-5 期非透析患者生命质量不同发展轨迹的影响因素。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. To investigate distinct developmental trajectories of quality of life in Stage 3-5 non-dialysis CKD patients. 2. To identify influencing factors of heterogeneous QoL trajectories in Stage 3-5 non-dialysis CKD patients based on the Wilson-Cleary model of health-related quality of life. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1. 年龄≥18 岁; 2. 符合 2012 年改善全球肾脏病预后组织 (KDIGO)关于 CKD 的定义标准及分期(GFR<60mL/min/1.73m2); 3. 未行肾脏替代治疗; 4. 认知功能正常,意识清楚,能正常沟通; 5. 知情同意,自愿参与本研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Aged >=18 years 2. Meeting the 2012 KDIGO diagnostic criteria for CKD with glomerular filtration rate (GFR) <60 mL/min/1.73m2 3. No prior renal replacement therapy (including hemodialysis, peritoneal dialysis, or kidney transplantation) 4. Intact cognitive function, clear consciousness, and ability to communicate effectively 5. Provision of written informed consent for voluntary participation |
||||||||||||||||||||||
|
排除标准: |
1. 慢性感染(结核、肝脓肿、肺脓肿)及恶性肿瘤患者; 2. 3 个月内有急性心肌梗塞、急性心功能不全、脑血管事件; 3. 2 周内急性感染(包括需要住院治疗的肺部感染、脓毒血症); 4. 孤立肾脏者; 5. 目前正在参加干预性临床研究。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with chronic infections (e.g., tuberculosis, liver abscess, lung abscess) or active malignancies 2. History of acute cardiovascular/cerebrovascular events within 3 months (including acute myocardial infarction, acute cardiac insufficiency, cerebrovascular events) 3. Acute infections requiring hospitalization within 2 weeks (including pneumonia, sepsis) 4. Anatomically solitary kidney 5. Current participation in interventional clinical trials |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-12-20 00:00:00至 To 2026-06-20 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-03-19 00:00:00 至 To 2025-04-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2026年12月31日,电子采集和管理系统(EDC) |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
December 31, 2026, Electronic Data Capture (EDC) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据由量表及病例采集,数据由医院电子信息系统管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data were collected by questionnaires and cases, and managed by the hospital electronic information system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |